Selfemra

maintenance therapy, Alcoholism, Depression + 12 more
Treatment
3 FDA approvals
20 Active Studies for Selfemra

What is Selfemra

FluoxetineThe Generic name of this drug
Treatment SummaryFluoxetine is an antidepressant medication approved by the FDA in 1987. It belongs to a class of drugs called selective serotonin reuptake inhibitors (SSRIs) and is primarily used to treat depression. However, it can also be prescribed for other mental health conditions.
Prozacis the brand name
Selfemra Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Prozac
Fluoxetine
1987
482

Approved as Treatment by the FDA

Fluoxetine, also known as Prozac, is approved by the FDA for 3 uses such as Unipolar Depression and Depression .
Unipolar Depression
Used to treat Major depressive disorder, recurrent episode in combination with Olanzapine
Depression
Used to treat Depression in combination with Olanzapine
Bipolar Disorder
Used to treat Bipolar 1 Disorder in combination with Olanzapine

Effectiveness

How Selfemra Affects PatientsFluoxetine works by blocking the serotonin transporter in the brain, which helps to maintain higher levels of serotonin. It has a low attraction to other receptors in the brain, which is why it is considered to have fewer side effects than other antidepressant drugs.
How Selfemra works in the bodyFluoxetine is a drug used to treat depression. It works by increasing the amount of serotonin, a chemical messenger in the brain, which helps improve mood. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) which means it stops the brain from taking in extra serotonin. It has a strong effect on serotonin, but only a weak effect on other neurotransmitters like noradrenaline and dopamine. It also interacts with the 5-HT2C receptor, which helps increase the levels of noradrenaline and dopamine in the brain.

When to interrupt dosage

The proposed measure of Selfemra is contingent upon the recognized condition, for instance Myoclonus, Bipolar Disorder and Unipolar Depression. The dosage is contingent upon the technique of delivery (e.g. Tablet, coated or Oral) listed in the table below.
Condition
Dosage
Administration
maintenance therapy
90.0 mg, , 40.0 mg, 20.0 mg, 10.0 mg, 20.0 mg/mL, 60.0 mg, 25.0 mg, 50.0 mg, 15.0 mg
Tablet, coated, Oral, Capsule, delayed release pellets, Capsule - Oral, , Tablet, Tablet, film coated - Oral, Capsule, delayed release - Oral, For solution, Solution - Oral, Tablet - Oral, Tablet, coated - Oral, Capsule, Liquid - Oral, Solution, Capsule, delayed release, Tablet, film coated, Kit, Liquid, Capsule, delayed release pellets - Oral, For solution - Oral
Depression
90.0 mg, , 40.0 mg, 20.0 mg, 10.0 mg, 20.0 mg/mL, 60.0 mg, 25.0 mg, 50.0 mg, 15.0 mg
Tablet, coated, Oral, Capsule, delayed release pellets, Capsule - Oral, , Tablet, Tablet, film coated - Oral, Capsule, delayed release - Oral, For solution, Solution - Oral, Tablet - Oral, Tablet, coated - Oral, Capsule, Liquid - Oral, Solution, Capsule, delayed release, Tablet, film coated, Kit, Liquid, Capsule, delayed release pellets - Oral, For solution - Oral
Panic Disorder (With or Without Agoraphobia)
90.0 mg, , 40.0 mg, 20.0 mg, 10.0 mg, 20.0 mg/mL, 60.0 mg, 25.0 mg, 50.0 mg, 15.0 mg
Tablet, coated, Oral, Capsule, delayed release pellets, Capsule - Oral, , Tablet, Tablet, film coated - Oral, Capsule, delayed release - Oral, For solution, Solution - Oral, Tablet - Oral, Tablet, coated - Oral, Capsule, Liquid - Oral, Solution, Capsule, delayed release, Tablet, film coated, Kit, Liquid, Capsule, delayed release pellets - Oral, For solution - Oral
moderate to severe symptoms
90.0 mg, , 40.0 mg, 20.0 mg, 10.0 mg, 20.0 mg/mL, 60.0 mg, 25.0 mg, 50.0 mg, 15.0 mg
Tablet, coated, Oral, Capsule, delayed release pellets, Capsule - Oral, , Tablet, Tablet, film coated - Oral, Capsule, delayed release - Oral, For solution, Solution - Oral, Tablet - Oral, Tablet, coated - Oral, Capsule, Liquid - Oral, Solution, Capsule, delayed release, Tablet, film coated, Kit, Liquid, Capsule, delayed release pellets - Oral, For solution - Oral
Disease
90.0 mg, , 40.0 mg, 20.0 mg, 10.0 mg, 20.0 mg/mL, 60.0 mg, 25.0 mg, 50.0 mg, 15.0 mg
Tablet, coated, Oral, Capsule, delayed release pellets, Capsule - Oral, , Tablet, Tablet, film coated - Oral, Capsule, delayed release - Oral, For solution, Solution - Oral, Tablet - Oral, Tablet, coated - Oral, Capsule, Liquid - Oral, Solution, Capsule, delayed release, Tablet, film coated, Kit, Liquid, Capsule, delayed release pellets - Oral, For solution - Oral
Myoclonus
90.0 mg, , 40.0 mg, 20.0 mg, 10.0 mg, 20.0 mg/mL, 60.0 mg, 25.0 mg, 50.0 mg, 15.0 mg
Tablet, coated, Oral, Capsule, delayed release pellets, Capsule - Oral, , Tablet, Tablet, film coated - Oral, Capsule, delayed release - Oral, For solution, Solution - Oral, Tablet - Oral, Tablet, coated - Oral, Capsule, Liquid - Oral, Solution, Capsule, delayed release, Tablet, film coated, Kit, Liquid, Capsule, delayed release pellets - Oral, For solution - Oral
Bipolar Disorder
90.0 mg, , 40.0 mg, 20.0 mg, 10.0 mg, 20.0 mg/mL, 60.0 mg, 25.0 mg, 50.0 mg, 15.0 mg
Tablet, coated, Oral, Capsule, delayed release pellets, Capsule - Oral, , Tablet, Tablet, film coated - Oral, Capsule, delayed release - Oral, For solution, Solution - Oral, Tablet - Oral, Tablet, coated - Oral, Capsule, Liquid - Oral, Solution, Capsule, delayed release, Tablet, film coated, Kit, Liquid, Capsule, delayed release pellets - Oral, For solution - Oral
Unipolar Depression
90.0 mg, , 40.0 mg, 20.0 mg, 10.0 mg, 20.0 mg/mL, 60.0 mg, 25.0 mg, 50.0 mg, 15.0 mg
Tablet, coated, Oral, Capsule, delayed release pellets, Capsule - Oral, , Tablet, Tablet, film coated - Oral, Capsule, delayed release - Oral, For solution, Solution - Oral, Tablet - Oral, Tablet, coated - Oral, Capsule, Liquid - Oral, Solution, Capsule, delayed release, Tablet, film coated, Kit, Liquid, Capsule, delayed release pellets - Oral, For solution - Oral
Bulimia Nervosa
90.0 mg, , 40.0 mg, 20.0 mg, 10.0 mg, 20.0 mg/mL, 60.0 mg, 25.0 mg, 50.0 mg, 15.0 mg
Tablet, coated, Oral, Capsule, delayed release pellets, Capsule - Oral, , Tablet, Tablet, film coated - Oral, Capsule, delayed release - Oral, For solution, Solution - Oral, Tablet - Oral, Tablet, coated - Oral, Capsule, Liquid - Oral, Solution, Capsule, delayed release, Tablet, film coated, Kit, Liquid, Capsule, delayed release pellets - Oral, For solution - Oral
Cataplexy
90.0 mg, , 40.0 mg, 20.0 mg, 10.0 mg, 20.0 mg/mL, 60.0 mg, 25.0 mg, 50.0 mg, 15.0 mg
Tablet, coated, Oral, Capsule, delayed release pellets, Capsule - Oral, , Tablet, Tablet, film coated - Oral, Capsule, delayed release - Oral, For solution, Solution - Oral, Tablet - Oral, Tablet, coated - Oral, Capsule, Liquid - Oral, Solution, Capsule, delayed release, Tablet, film coated, Kit, Liquid, Capsule, delayed release pellets - Oral, For solution - Oral
Alcoholism
90.0 mg, , 40.0 mg, 20.0 mg, 10.0 mg, 20.0 mg/mL, 60.0 mg, 25.0 mg, 50.0 mg, 15.0 mg
Tablet, coated, Oral, Capsule, delayed release pellets, Capsule - Oral, , Tablet, Tablet, film coated - Oral, Capsule, delayed release - Oral, For solution, Solution - Oral, Tablet - Oral, Tablet, coated - Oral, Capsule, Liquid - Oral, Solution, Capsule, delayed release, Tablet, film coated, Kit, Liquid, Capsule, delayed release pellets - Oral, For solution - Oral
Anorexia Nervosa
90.0 mg, , 40.0 mg, 20.0 mg, 10.0 mg, 20.0 mg/mL, 60.0 mg, 25.0 mg, 50.0 mg, 15.0 mg
Tablet, coated, Oral, Capsule, delayed release pellets, Capsule - Oral, , Tablet, Tablet, film coated - Oral, Capsule, delayed release - Oral, For solution, Solution - Oral, Tablet - Oral, Tablet, coated - Oral, Capsule, Liquid - Oral, Solution, Capsule, delayed release, Tablet, film coated, Kit, Liquid, Capsule, delayed release pellets - Oral, For solution - Oral
Depression
90.0 mg, , 40.0 mg, 20.0 mg, 10.0 mg, 20.0 mg/mL, 60.0 mg, 25.0 mg, 50.0 mg, 15.0 mg
Tablet, coated, Oral, Capsule, delayed release pellets, Capsule - Oral, , Tablet, Tablet, film coated - Oral, Capsule, delayed release - Oral, For solution, Solution - Oral, Tablet - Oral, Tablet, coated - Oral, Capsule, Liquid - Oral, Solution, Capsule, delayed release, Tablet, film coated, Kit, Liquid, Capsule, delayed release pellets - Oral, For solution - Oral
Obsessive-Compulsive Disorder
90.0 mg, , 40.0 mg, 20.0 mg, 10.0 mg, 20.0 mg/mL, 60.0 mg, 25.0 mg, 50.0 mg, 15.0 mg
Tablet, coated, Oral, Capsule, delayed release pellets, Capsule - Oral, , Tablet, Tablet, film coated - Oral, Capsule, delayed release - Oral, For solution, Solution - Oral, Tablet - Oral, Tablet, coated - Oral, Capsule, Liquid - Oral, Solution, Capsule, delayed release, Tablet, film coated, Kit, Liquid, Capsule, delayed release pellets - Oral, For solution - Oral
Premature Ejaculation
90.0 mg, , 40.0 mg, 20.0 mg, 10.0 mg, 20.0 mg/mL, 60.0 mg, 25.0 mg, 50.0 mg, 15.0 mg
Tablet, coated, Oral, Capsule, delayed release pellets, Capsule - Oral, , Tablet, Tablet, film coated - Oral, Capsule, delayed release - Oral, For solution, Solution - Oral, Tablet - Oral, Tablet, coated - Oral, Capsule, Liquid - Oral, Solution, Capsule, delayed release, Tablet, film coated, Kit, Liquid, Capsule, delayed release pellets - Oral, For solution - Oral

Warnings

Selfemra Contraindications
Condition
Risk Level
Notes
Toxoplasma Infections
Do Not Combine
Toxoplasma Infections
Do Not Combine
Toxoplasma Infections
Do Not Combine
Toxoplasma Infections
Do Not Combine
Toxoplasma Infections
Do Not Combine
There are 20 known major drug interactions with Selfemra.
Common Selfemra Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Fluoxetine.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Fluoxetine.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Fluoxetine.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Fluoxetine.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Fluoxetine.
Selfemra Toxicity & Overdose RiskIn a report of 234 fluoxetine overdoses, the most common side effects were drowsiness, shaking, rapid heartbeat, nausea, and vomiting. Most of the time, aggressive supportive care is all that is needed to reverse the effects. However, more severe reactions can occur when taking large doses of fluoxetine or when combined with other drugs. These reactions can include seizures, symptoms similar to serotonin syndrome, and muscle breakdown.

Selfemra Novel Uses: Which Conditions Have a Clinical Trial Featuring Selfemra?

Currently, 881 active trials are examining the potential of Selfemra to manage Disease, Anorexia Nervosa and assist in maintenance therapy.
Condition
Clinical Trials
Trial Phases
Depression
201 Actively Recruiting
Phase 2, Not Applicable, Phase 3, Phase 1, Phase 4, Early Phase 1
Disease
0 Actively Recruiting
Anorexia Nervosa
0 Actively Recruiting
maintenance therapy
0 Actively Recruiting
Cataplexy
6 Actively Recruiting
Phase 2, Phase 3, Not Applicable
Bulimia Nervosa
14 Actively Recruiting
Not Applicable, Phase 2, Phase 3, Early Phase 1
Bipolar Disorder
1 Actively Recruiting
Phase 4
Panic Disorder (With or Without Agoraphobia)
0 Actively Recruiting
moderate to severe symptoms
0 Actively Recruiting
Myoclonus
2 Actively Recruiting
Phase 2, Not Applicable
Depression
644 Actively Recruiting
Phase 2, Not Applicable, Phase 3, Phase 1, Early Phase 1, Phase 4
Obsessive-Compulsive Disorder
15 Actively Recruiting
Not Applicable, Phase 3
Unipolar Depression
52 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3, Phase 1
Premature Ejaculation
0 Actively Recruiting
Alcoholism
8 Actively Recruiting
Phase 3, Not Applicable, Phase 2

Selfemra Reviews: What are patients saying about Selfemra?

4.7Patient Review
3/20/2009
Selfemra for Depression
I was experiencing depression and struggling to find solutions to our financial problems. This medication has helped me to cope better and see the bright side of things. I am also a caregiver for an elderly parent with Alzheimer's disease.
4.3Patient Review
2/13/2009
Selfemra for "Change of Life" Signs
This drug has really helped me to better regulate my mood swings. In less than a month, I started seeing real results that have stuck around.
2.3Patient Review
11/19/2008
Selfemra for Premenstrual Disorder with a State of Unhappiness
I've been on this medication for over a year and I constantly feel like I have the flu. No improvement whatsoever. The only brand that doesn't give me any side effects is Sarafem, but it's much more expensive.
2Patient Review
12/30/2008
Selfemra for "Change of Life" Signs
I was taking Sarafem, but it became too expensive so I switched to this generic brand. Unfortunately, I just feel tired all the time now.

Patient Q&A Section about selfemra

How long does fluoxetine last?

"This means that after stopping the prescription, it will take four to six days for the drug to lose half of its effectiveness." - Anonymous Online Contributor

Unverified Answer

What does antidepressants do?

"The chemicals known as neurotransmitters are increased in activity by antidepressant medications. This increased activity appears to help reduce symptoms related to depression and anxiety." - Anonymous Online Contributor

Unverified Answer

What is Sarafem used for?

"Sarafem is a prescription medication used to treat symptoms associated with major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. Sarafem may be used as a standalone treatment or in conjunction with other medications. Sarafem falls under a class of drugs known as antidepressants and SSRIs." - Anonymous Online Contributor

Unverified Answer

Can you drink while taking fluoxetine?

"You can drink alcohol while taking fluoxetine, but it may make you feel sleepy. It might be best to stop drinking alcohol for the first few days of treatment until you see how the medicine affects you." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Selfemra

Image of Icahn School of Medicine at Mount Sinai, Mount Sinai West in New York, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Deep Brain Stimulation (DBS) For Treatment Resistant Depressionfor Major Depressive Disorder

25 - 70
All Sexes
New York, NY
Of the estimated 30 million Americans who suffer from Major Depressive Disorder, approximately 10% are considered treatment resistant. Deep brain stimulation (DBS) to a region of the brain called the subcallosal cingulate (SCC) is an emerging strategy for treatment resistant depression (TRD), which involves placement of electrodes in a specific region of the brain and stimulating that area with electricity. This is believed to reset the brain network responsible for symptoms and results in a significant antidepressant response. A series of open-label studies have demonstrated sustained, long-term antidepressant effects in 40-60% of patients who received this treatment. A challenge to the effective dissemination of this fledgling treatment is the absence of biomarkers (objective, measureable indications of the state of the body and brain) to guide device placement and select stimulation parameters during follow-up care. By using a DBS device called the Percept PC (Medtronic, Inc) which has the ability to both deliver stimulation to and record electrical signals directly from the brain, this study aims to identify changes in local field potentials (LFPs), specific electrical signals that are thought to represent how the brain communicates information from one region to another, to see how this relates to DBS parameter settings and patient depressive symptomatology. The goal of this study is to study LFPs before and during active DBS stimulation to identify changes that correlate with the antidepressant effects of SCC DBS. The study team will recruit 10 patients with TRD and implant them with the Percept PC system. Participants will be asked to complete short questionnaires and collect LFP data twice daily for the first year of the study, as well as have weekly in person research procedures and assessments with the study team for up to one year. These include meetings with the study psychiatrist, psychologist, symptom ratings, and movement, voice, and video recordings. A brief discontinuation experiment will be conducted after 6 months of stimulation, in which the stimulation will be turned off and patterns of LFP changes will be recorded. The entire study is expected to last about 5 years, parcellated into several study phases. All participants are required to live in the New York metropolitan area for the first several months of the study.
Recruiting
Has No Placebo
Icahn School of Medicine at Mount Sinai, Mount Sinai WestHelen Mayberg, MD
Have you considered Selfemra clinical trials? We made a collection of clinical trials featuring Selfemra, we think they might fit your search criteria.
Have you considered Selfemra clinical trials? We made a collection of clinical trials featuring Selfemra, we think they might fit your search criteria.
Have you considered Selfemra clinical trials? We made a collection of clinical trials featuring Selfemra, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top